Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Recruiting 40 enrolled Virginia Commonwealth University

NaSingle-groupOpen-labelTreatment

Summary

Evaluate frequency of adverse events that lead to chemotherapy discontinuation in vulnerable older adults with recurrent/metastatic PD-L1 TPS\<50% NSCLC patients who receive reduced dose chemotherapy in combination with immunotherapy.

Timeline

Start: 2025-02-11
Primary completion: 2030-07-30
Completion: 2033-07-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	3 unknown	Intravenous
Subject	Paclitaxel	Small molecule	135 mg/m2	Intravenous
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous
Subject	Pemetrexed	Small molecule	375 mg/m2	Intravenous

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

Summary

Timeline

Drugs

Indications